Infliximab (IFX) treatment intensification, consisting of dose escalation or interval shortening, is effective for restoring clinical response in patients with Crohn’s disease (CD). However, clinical data on the timing of IFX treatment intensification are sparse. We aimed to evaluate the timing of IFX treatment intensification for clinical response in patients with CD.